Erez Aminov - 31 Dec 2025 Form 5 Insider Report for MIRA PHARMACEUTICALS, INC. (MIRA)

Role
CEO and Chairman, Director
Signature
/s/ Erez Aminov
Issuer symbol
MIRA
Transactions as of
31 Dec 2025
Net transactions value
-$522,945
Form type
5
Filing time
17 Feb 2026, 20:30:02 UTC
Previous filing
03 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Aminov Erez CEO and Chairman, Director C/O MIRA PHARMACEUTICALS, INC., 1200 BRICKELL AVE. SUITE 1950 #1183, MIAMI /s/ Erez Aminov 17 Feb 2026 0001986112

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIRA Common Stock Award $90,625 +62,500 +1.8% $1.45 3,530,166 26 Mar 2025 Direct F1, F2
transaction MIRA Common Stock Award $90,625 +62,500 +1.8% $1.45 3,592,666 26 Mar 2025 Direct F1, F2
transaction MIRA Common Stock Options Exercise $272,130 +234,595 +6.5% $1.16 3,827,259 16 Oct 2025 Direct F1, F3
transaction MIRA Common Stock Options Exercise $318,360 +379,000 +9.9% $0.8400 4,206,259 16 Oct 2025 Direct F1, F4
transaction MIRA Common Stock Sale $1,294,685 -613,595 -15% $2.11 3,592,666 16 Oct 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIRA Stock Options (right to buy) Options Exercise $0 +234,595 $0.000000 234,595 16 Oct 2025 Common Stock $234,595 $1.16 Direct F3
transaction MIRA Stock Options (right to buy) Options Exercise $0 +379,000 $0.000000 379,000 16 Oct 2025 Common Stock 379,000 $0.8400 Direct F4
transaction MIRA Stock Options (right to buy) Award $0 +3,155,170 $0.000000 3,155,170 17 Dec 2025 Common Stock 3,155,170 $1.45 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of Issuer's common stock, par value $0.0001 ("Common Stock") that should have been reported on Form 4.
F2 Represents grants of RSUs with underlying shares of Common Stock under the Issuer's 2024 Omnibus Equity Incentive Plan (the "Plan"), for awards granted in accordance with the Issuer's CEO's Long-Term Incentive Plan. The RSUs hereunder vested upon issuance.
F3 Represents exercise of 234,595 stock options to purchase Common Stock under the Plan that were issued to the Reporting Person on March 26, 2024, with 50% of such options vesting on the six-month anniversary date of the grant, and the remaining half vesting on the one-year anniversary date of the grant, pursuant to a grant under the Plan at an exercise price of $1.16 each.
F4 Represents exercise of 379,000 stock options to purchase Common Stock under the Plan that were issued to the Reporting Person on May 28, 2024 that were vested in full and became exercisable on the same date, pursuant to a grant under the Plan at an exercise price of $0.84 each.
F5 Represents grants of options with underlying shares of Common Stock under the Plan, for awards granted in accordance with the Issuer's CEO's Long-Term Incentive Plan. The options hereunder vested upon issuance.